Hermes Vector

Health

FDA Clears Bracco and Avicenna.AI Brain Aneurysm Detection Software

The FDA has granted 510(k) clearance to UPTUNITY | Aneurysm, an AI-enabled software from Bracco and Avicenna.AI for detecting and assessing brain aneurysms on head CTA images.

By Hermes Vector

Checked against 3 sourcesradiologybusiness.comitnonline.compressreleasehub.pa.media
Illustration for: FDA Clears Bracco and Avicenna.AI Brain Aneurysm Detection Software

In brief

  • The FDA granted 510(k) clearance to UPTUNITY | Aneurysm, developed by Bracco and Avicenna.AI.
  • The software identifies suspected saccular brain aneurysms greater than 3 mm on head CTA images.
  • The software provides quantitative measurements and comparisons for follow-up assessment of known aneurysms.
  • Bracco and Avicenna.AI announced their strategic partnership in March 2026.

FDA Clears Bracco and Avicenna.AI Brain Aneurysm Detection Software

The U.S. Food and Drug Administration has granted 510(k) clearance to UPTUNITY | Aneurysm, an AI-enabled software for brain aneurysm detection and assessment developed by Bracco in collaboration with Avicenna.AI.

Product details

UPTUNITY | Aneurysm is the first offering within Bracco's new UPTUNITY portfolio of AI-enabled clinical decision support solutions. The software is designed to support medical specialists in detecting and assessing brain aneurysms on cerebral arteries computed tomography angiography (CTA) images.

The computer-assisted detection (CADe) and diagnosis (CADx) software identifies suspected saccular brain aneurysms greater than 3 mm on head CTA images and provides information about their presence, location and size for assessment and characterization. For known aneurysms, the follow-up functionality provides quantitative measurements and comparison between examinations to assess changes over time.

Company statements

"A small incidental aneurysm on a head CTA can easily be overlooked when the worklist keeps growing," said Cosimo DePinto, Executive Vice President, Marketing & Commercial Operations, Bracco Americas. "UPTUNITY | Aneurysm works inside the reading environment radiologists already know and helps find the aneurysm hiding in the CT scan. The clinical decision stays where it belongs: with the radiologist."

"For a patient with an unruptured aneurysm, the follow-up scan always brings the same question: has it changed?" said Fabio Tedoldi, PhD, Head of Global Research & Development, Bracco Imaging. "UPTUNITY | Aneurysm supports physicians from first detection through subsequent monitoring, with comparable readings at every exam. Precision, to us, means not only finding, but following up."

Background and availability

An estimated one in 50 U.S. adults has an unruptured brain aneurysm, a condition that is often asymptomatic. Bracco and Avicenna.AI announced their strategic partnership in March 2026 to advance AI applications in contrast-enhanced computed tomography. The companies are preparing for the commercial introduction of UPTUNITY | Aneurysm in the United States, with Avicenna.AI leading promotion and commercial distribution.

The software will be showcased at the Radiological Society of North America (RSNA) 2026 Annual Meeting, taking place November 29-December 3 in Chicago. UPTUNITY | Aneurysm has received 510(k) clearance from the FDA under K262062 and K262147. UPTUNITY | Aneurysm Detection and UPTUNITY | Aneurysm Management are the commercial names for CINA-Aneurysm (K262062) and CINA-Aneurysm+ (K262147), respectively.


Sources

This article was drafted with AI assistance and checked against the sources above. Company claims are reported as claims. Cover image is AI-generated.

The day's checked news, by email

One short email a day with the top stories. Free, and you can unsubscribe in one click.

Or follow for the latest news:

How do you feel about this story?

Comments 0

No comments yet. Start the discussion.

Health

Avian influenza investigation under way at Co Tyrone poultry premises

DAERA is investigating a suspected avian influenza case at a commercial poultry premises in County Tyrone after significant mortality and clinical signs were observed. Samples have been sent to the UK National Reference Laboratory at Weybridge, with results expected on Monday.

Checked against 6 sourcesirishtimes.comagriland.ieireland-live.ie+3 more